Keay Nakae
Stock Analyst at Chardan Capital
(3.18)
# 1,086
Out of 4,748 analysts
201
Total ratings
30.3%
Success rate
6.85%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Maintains: Buy | $25 | $2.18 | +1,047.05% | 13 | Jan 29, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $13.99 | +257.53% | 8 | Jan 10, 2025 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $30 → $20 | $1.71 | +1,069.59% | 12 | Dec 20, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $2.11 | +89.57% | 13 | Dec 12, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $20.15 | +197.84% | 17 | Dec 12, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 | $5.11 | +976.32% | 10 | Dec 10, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $4.5 → $5 | $3.36 | +49.03% | 11 | Nov 20, 2024 | |
| ALUR Allurion Technologies | Downgrades: Neutral | n/a | $5.32 | - | 4 | Nov 14, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $1.25 | $0.83 | +51.46% | 8 | Nov 13, 2024 | |
| FEMY Femasys | Maintains: Buy | $10 → $8 | $1.15 | +595.65% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.64 | +254.61% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 | $32.57 | +99.57% | 12 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 | $5.92 | +136.49% | 14 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 | $274.94 | +9.11% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.20 | +172.73% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.46 | +1,200.11% | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.90 | +72.71% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.34 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $20.00 | -70.00% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.75 | +2,569.87% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $11.15 | +393.27% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $10.53 | -5.03% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $15.34 | +470.59% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.75 | +1,635.88% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.06 | +1,844.48% | 2 | Jun 30, 2020 |
SAB Biotherapeutics
Jan 29, 2025
Maintains: Buy
Price Target: $25
Current: $2.18
Upside: +1,047.05%
Dyne Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $50
Current: $13.99
Upside: +257.53%
Sonnet BioTherapeutics Holdings
Dec 20, 2024
Maintains: Buy
Price Target: $30 → $20
Current: $1.71
Upside: +1,069.59%
ProQR Therapeutics
Dec 12, 2024
Maintains: Buy
Price Target: $4
Current: $2.11
Upside: +89.57%
Arrowhead Pharmaceuticals
Dec 12, 2024
Maintains: Buy
Price Target: $60
Current: $20.15
Upside: +197.84%
Silence Therapeutics
Dec 10, 2024
Maintains: Buy
Price Target: $55
Current: $5.11
Upside: +976.32%
Arbutus Biopharma
Nov 20, 2024
Maintains: Buy
Price Target: $4.5 → $5
Current: $3.36
Upside: +49.03%
Allurion Technologies
Nov 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.32
Upside: -
Seres Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $1.25
Current: $0.83
Upside: +51.46%
Femasys
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.15
Upside: +595.65%
Nov 13, 2024
Maintains: Buy
Price Target: $20
Current: $5.64
Upside: +254.61%
Nov 13, 2024
Maintains: Buy
Price Target: $65
Current: $32.57
Upside: +99.57%
Nov 7, 2024
Maintains: Buy
Price Target: $14
Current: $5.92
Upside: +136.49%
Nov 1, 2024
Maintains: Buy
Price Target: $300
Current: $274.94
Upside: +9.11%
Aug 9, 2024
Maintains: Buy
Price Target: $6
Current: $2.20
Upside: +172.73%
Aug 7, 2024
Maintains: Buy
Price Target: $7 → $6
Current: $0.46
Upside: +1,200.11%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $2.90
Upside: +72.71%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $20.00
Upside: -70.00%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.75
Upside: +2,569.87%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $11.15
Upside: +393.27%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $10.53
Upside: -5.03%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $15.34
Upside: +470.59%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.75
Upside: +1,635.88%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.06
Upside: +1,844.48%